Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amel Kime

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Gynecologic Oncology|April 14, 2025
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysisJulie Berthet, Amel Kime, Bruno Borghese, et al.
Indian Journal of Urology : IJU : Journal of the Urological Society of India|May 10, 2024
Inflammatory myofibroblastic tumor of the urinary bladder: A systematic review of the literature and report of a caseLory Hage, Michael A O'Donnell, Mohamad Abou Chakra, et al.
F&S Reports|June 22, 2026
Polypoid endometrioma mimicking malignant transformation: a case report and systematic reviewGuillaume Parpex, Louis Marcellin, Joëlle Uzan-Augui, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 14, 2025
Identification of a very-high risk subgroup of localized endometrial carcinoma before surgery using circulating tumor DNA: a proof-of-concept studyAntoine Gaudet Chardonnet, Bruno Borghese, Jérôme Alexandre, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Gynecologic Oncology|April 14, 2025
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysisJulie Berthet, Amel Kime, Bruno Borghese, et al.
Indian Journal of Urology : IJU : Journal of the Urological Society of India|May 10, 2024
Inflammatory myofibroblastic tumor of the urinary bladder: A systematic review of the literature and report of a caseLory Hage, Michael A O'Donnell, Mohamad Abou Chakra, et al.
F&S Reports|June 22, 2026
Polypoid endometrioma mimicking malignant transformation: a case report and systematic reviewGuillaume Parpex, Louis Marcellin, Joëlle Uzan-Augui, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 14, 2025
Identification of a very-high risk subgroup of localized endometrial carcinoma before surgery using circulating tumor DNA: a proof-of-concept studyAntoine Gaudet Chardonnet, Bruno Borghese, Jérôme Alexandre, et al.
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Pageof 1